Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and
uncontrolled movements called dyskinesias. A drug called amantadine can reduce these
movements. To date, there are no objective measures of these movements. The purpose of this
study is to measure the reduction of the movements by amantadine and/or topiramate using an
objective measure.